Alessandra Decio
Preclinical R&D Department
Milan, Italy
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
LKB1 Dysregulation in Duchenne Muscular Dystrophy Models: Disease Specificity and Epigenetic Control by HDAC Inhibitors.
Journal: Annals of the New York Academy of Sciences
Published: November 21, 2025
Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: July 23, 2025
Melanoma extracellular vesicles membrane coated nanoparticles as targeted delivery carriers for tumor and lungs.
Journal: Materials today. Bio
Published: October 21, 2024
Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness.
Journal: Cell death & disease
Published: April 09, 2024
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.
Journal: Cell death & disease
Published: November 09, 2023
Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice.
Journal: Molecules (Basel, Switzerland)
Published: October 10, 2023
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
Journal: Cancer research communications
Published: October 25, 2022
Endoplasmic reticulum oxidoreductin 1-alpha deficiency and activation of protein translation synergistically impair breast tumour resilience.
Journal: British journal of pharmacology
Published: January 17, 2022
L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling.
Journal: Journal of experimental & clinical cancer research : CR
Published: July 16, 2021
Last Updated: 09/26/2026